Purple Biotech Ltd
PPBT0.818USD
+0.077+10.45%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
464.67MMarket Cap
LossP/E TTM
More Details of Purple Biotech Ltd Company
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Purple Biotech Ltd Info
Ticker SymbolPPBT
Company namePurple Biotech Ltd
IPO dateSep 03, 1978
CEOMr. Gil Efron, CPA
Number of employees9
Security typeOrdinary Share
Fiscal year-endSep 03
Address4 Oppenheimer St.
CityREHOVOT
Stock exchangeTel Aviv Stock Exchange
CountryIsrael
Postal code7670104
Phone97239333121
Websitehttps://purple-biotech.com/
Ticker SymbolPPBT
IPO dateSep 03, 1978
CEOMr. Gil Efron, CPA
Company Executives of Purple Biotech Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Steven Steinberg
Mr. Steven Steinberg
Independent Director
Independent Director
--
--
Mr. Avraham Ben-Tzvi
Mr. Avraham Ben-Tzvi
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Yisrael Gewirtz
Mr. Yisrael Gewirtz
Internal Auditor
Internal Auditor
--
--
Dr. Eric K. Rowinsky, M.D.
Dr. Eric K. Rowinsky, M.D.
Chairman of the Board
Chairman of the Board
--
--
Mr. Gil Efron, CPA
Mr. Gil Efron, CPA
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Itzhak Israel
Mr. Itzhak Israel
Director
Director
--
--
Dr. Bertrand Liang
Dr. Bertrand Liang
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Arie Weber
Mr. Arie Weber
Independent Director
Independent Director
--
--
Ms. Revital Stern-Raff
Ms. Revital Stern-Raff
Independent Director
Independent Director
--
--
Dr. Hadas Reuveni
Dr. Hadas Reuveni
Founder and Chief Technology Officer of TyrNovo (a subsidiary)
Founder and Chief Technology Officer of TyrNovo (a subsidiary)
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Steven Steinberg
Mr. Steven Steinberg
Independent Director
Independent Director
--
--
Mr. Avraham Ben-Tzvi
Mr. Avraham Ben-Tzvi
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Yisrael Gewirtz
Mr. Yisrael Gewirtz
Internal Auditor
Internal Auditor
--
--
Dr. Eric K. Rowinsky, M.D.
Dr. Eric K. Rowinsky, M.D.
Chairman of the Board
Chairman of the Board
--
--
Mr. Gil Efron, CPA
Mr. Gil Efron, CPA
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Itzhak Israel
Mr. Itzhak Israel
Director
Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Oct 24
Updated: Fri, Oct 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
6.51%
Orca Capital GmbH
3.30%
UBS Financial Services, Inc.
0.25%
GAMMA Investing LLC
0.14%
BNP Paribas Securities Corp. North America
0.07%
Other
89.74%
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
6.51%
Orca Capital GmbH
3.30%
UBS Financial Services, Inc.
0.25%
GAMMA Investing LLC
0.14%
BNP Paribas Securities Corp. North America
0.07%
Other
89.74%
Shareholder Types
Shareholders
Proportion
Corporation
6.51%
Investment Advisor
3.57%
Investment Advisor/Hedge Fund
0.14%
Research Firm
0.12%
Other
89.67%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
40
355.08K
3.82%
+98.77K
2025Q2
37
55.19K
1.82%
-201.60K
2025Q1
39
103.31K
6.70%
-153.87K
2024Q4
41
133.07K
5.02%
-58.34K
2024Q3
39
222.98K
11.78%
+111.64K
2024Q2
39
147.98K
8.71%
+1.90K
2024Q1
40
184.47K
11.90%
+40.99K
2023Q4
40
174.27K
11.63%
+106.33K
2023Q3
38
64.91K
3.14%
-5.47K
2023Q2
37
13.88K
1.30%
-49.49K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lincoln Alternative Strategies LLC
605.00K
6.7%
+605.00K
--
Sep 04, 2025
Orca Capital GmbH
306.39K
3.39%
+306.39K
--
Sep 07, 2025
UBS Financial Services, Inc.
23.14K
0.26%
+119.00
+0.52%
Jun 30, 2025
GAMMA Investing LLC
12.65K
0.14%
+8.22K
+185.64%
Sep 30, 2025
BNP Paribas Securities Corp. North America
6.28K
0.07%
+900.00
+16.74%
Jun 30, 2025
Morgan Stanley & Co. LLC
4.57K
0.05%
+100.00
+2.24%
Jun 30, 2025
Rhumbline Advisers Ltd. Partnership
1.08K
0.01%
+275.00
+34.16%
Jun 30, 2025
Raymond James Financial Services Advisors, Inc.
555.00
0.01%
+555.00
--
Jun 30, 2025
RBC Dominion Securities, Inc.
107.00
0%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 06, 2024
Merger
20→1
Sep 06, 2024
Merger
20→1
Sep 06, 2024
Merger
20→1
Sep 06, 2024
Merger
20→1
Aug 13, 2020
Merger
10→1
Aug 13, 2020
Merger
10→1
Date
Type
Ratio
Sep 06, 2024
Merger
20→1
Sep 06, 2024
Merger
20→1
Sep 06, 2024
Merger
20→1
Sep 06, 2024
Merger
20→1
Aug 13, 2020
Merger
10→1
Aug 13, 2020
Merger
10→1
Aug 13, 2020
Merger
10→1
Aug 13, 2020
Merger
10→1
